Pannex Therapeutics is a pioneer biopharmaceutical company totally focused on the development of a novel therapeutic class of Pannexin 1 channel (Panx1) blockers. Pannex is developing a platform of small molecules that blocks this exciting new pharmacological target, Panx1 channels.

With potential applications in many therapeutic areas, the initial focus is on chronic pain treatment. The company is currently developing a first-in-class, selective and highly potent oral Panx1 channel blocker, for the treatment of chronic pain and prevention of opioid addiction.